BioTuesdays

Taysha gets FDA rare pediatric and orphan drug designations for epilepsy

Taysha Gene Therapies’ (NASDAQ:TSHA) TSHA-103 received FDA rare pediatric and orphan drug designations for the treatment of SLC6A1-related epilepsy.

SLC6A1-related epilepsy is caused by the loss of function of one copy of the SLC6A1 gene. TSHA-103 is an adeno-associated virus serotype 9-base gene therapy.

“Haploinsufficiency in the SLC6A1 gene has been identified as a cause of genetic epilepsy, yet there remains a lack of approved disease-modifying therapies,” Stephen Gray, Ph.D., Taysha’s CSO, said in a statement.

“The designations highlight the innovation of TSHA-103 and the importance of developing a treatment for patients living with this devastating disease,” he added. 

The company’s TSHA-101, TSHA-102, TSHA-118 and TSHA-104 gene therapy candidates previously received rare pediatric and orphan drug designations for the treatment of GM2 gangliosidosis, Rett syndrome, infantile Batten disease and Leigh syndrome, respectively.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.